Active Ingredient History
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. It is not used on warts inside the vagina, penis, or rectum. Imiquimod is also used to treat a skin condition of the face and scalp called actinic keratoses. Imiquimod can also be used to treat certain types of skin cancer called superficial basal cell carcinoma. Imiquimod is particularly useful on areas where surgery or other treatments may be difficult, complicated or otherwise undesirable, especially the face and lower legs. Imiquimod's mechanism of action is via stimulation of innate and acquired immune responses, which ultimately leads to inflammatory cell infiltration within the field of drug application followed by apoptosis of diseased tissue. Imiquimod does not have direct antiviral activity. Studies of mice show that imiquimod may induce cytokines, including interferon-alpha (IFNA) as well as several IFNA genes (IFNA1, IFNA2, IFNA5, IFNA6, and IFNA8) as well as the IFNB gene. Imiquimod also induced the expression of interleukin (IL)-6, IL-8, and tumor necrosis factor alpha genes. In the treatment of basal cell carcinoma, Imiquimod appears to act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells. In treating basal cell carcinoma it may increase the infiltration of lymphocytes, dendritic cells, and macrophages into the tumor lesion. Imiquimod is used for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alopecia Areata (Phase 4)
Anus Neoplasms (Phase 3)
Astrocytoma (Phase 1)
Bowen's Disease (Phase 2/Phase 3)
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Breast Neoplasms, Male (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Basal Cell (Phase 4)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma in Situ (Phase 2)
Carcinoma, Merkel Cell (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 1)
Carcinoma, Renal Cell (Phase 1)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 1)
Cervical Intraepithelial Neoplasia (Phase 3)
Cheilitis (Phase 4)
Cholangiocarcinoma (Phase 1)
Colorectal Neoplasms (Phase 1/Phase 2)
Condylomata Acuminata (Phase 4)
Diffuse Intrinsic Pontine Glioma (Phase 1)
Ependymoma (Phase 1)
Esophageal Neoplasms (Phase 1)
Fallopian Tube Neoplasms (Phase 2)
Genital Neoplasms, Female (Phase 2)
Glioblastoma (Phase 1)
Glioma (Phase 1)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1)
Hemangioma, Capillary (Phase 2)
Hepatitis B (Phase 2/Phase 3)
HIV (Phase 4)
HIV Infections (Phase 3)
Human papillomavirus 16 (Phase 2)
Hutchinson's Melanotic Freckle (Phase 4)
Inflammatory Bowel Diseases (Phase 2/Phase 3)
Influenza, Human (Phase 4)
Influenza in Birds (Phase 1)
Influenza Vaccines (Phase 2)
Keloid (Phase 2)
Keratosis (Phase 4)
Leishmaniasis, Cutaneous (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Liver Cirrhosis (Phase 2)
Lymphoma, T-Cell, Cutaneous (Early Phase 1)
Malaria, Falciparum (Early Phase 1)
Medulloblastoma (Phase 1)
Melanoma (Phase 3)
Microsatellite Instability (Phase 1)
Mouth Neoplasms (Early Phase 1)
Mycosis Fungoides (Early Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 4)
Neoplasms, Squamous Cell (Phase 1)
Neurofibroma (Phase 1)
Neurofibromatosis 1 (Phase 1)
Osteosarcoma (Phase 1)
Ovarian Neoplasms (Phase 2)
Paget Disease, Extramammary (Phase 3)
Papillomaviridae (Phase 4)
Papillomavirus Infections (Phase 3)
Port-Wine Stain (Phase 2)
Precancerous Conditions (Phase 2)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 1)
Renal Insufficiency (Phase 2/Phase 3)
Sarcoma (Phase 1)
Scleroderma, Localized (Phase 3)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 1)
Squamous Intraepithelial Lesions (Phase 3)
Stomach Neoplasms (Phase 1)
Urinary Bladder (Phase 1)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Dysplasia (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Vaccination (Phase 2)
Vaccines (Phase 2)
Vaginal Diseases (Phase 2)
Vulvar Neoplasms (Phase 3)
Warts (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
